Phathom Pharmaceuticals (PHAT) Change in Receivables (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Change in Receivables data on file, last reported at $2.6 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at $2.6 million, up 206.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.4 million (up 36.56% YoY), and the FY2025 annual result was $39.3 million, up 5.84% from the prior year.
• Change in Receivables declined to $2.6 million in Q1 2026 per PHAT's latest filing, from $22.3 million in the prior quarter.
• Over five years, Change in Receivables peaked at $22.3 million in Q4 2025 and troughed at -$2.4 million in Q1 2025.
• A 4-year average of $8.1 million and a median of $5.8 million in 2024 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2024 and 2025: Change in Receivables surged 984.0% in 2024, then plunged 208.47% in 2025.
• A 4-year view of Change in Receivables shows it stood at $1.6 million in 2023, then surged by 984.0% to $17.7 million in 2024, then rose by 25.89% to $22.3 million in 2025, then tumbled by 88.38% to $2.6 million in 2026.
• Business Quant data shows PHAT's Change in Receivables at $2.6 million in Q1 2026, $22.3 million in Q4 2025, and $4.5 million in Q3 2025.